Treatment

A new study found that starting patients on a lower dose of enfortumab vedotin (Padcev) with pembrolizumab (Keytruda) can improve tolerability without reducing survival in advanced urothelial carcinoma. Researchers analyzed data from 496 patients treated with this first-line combination and compared standard dosing with lower starting doses. Patients who began at a reduced dose had fewer […]

The FDA has accepted a supplemental biologics license application for datopotamab deruxtecan (Dato-DXd) as a first-line treatment for adults with unresectable or metastatic triple-negative breast cancer who cannot receive immunotherapy. A regulatory decision is expected in the second quarter of 2026. The application is supported by Phase 3 TROPION-Breast02 trial results showing that Dato-DXd outperformed

Privo Technologies announced that its intraoperative cisplatin patch, PRV211, met the primary safety endpoint in Arm 2 of the Phase 2/3 CLN-004 trial for patients with invasive oral cavity cancer. In the earlier phase 1/2 group of eight patients, no treatment-related serious adverse events, systemic toxicities, or dose-limiting toxicities were observed, and wound healing was

Interim results from a Phase 2a trial testing a combination of atebimetinib with modified gemcitabine/nabpaclitaxel (mGnP) have shown promising survival outcomes in patients with advanced pancreatic cancer. The study reported a 64 % overall survival rate at 12 months, a significant improvement over historical benchmarks achieved with standard chemotherapy alone. This combination therapy pairs traditional chemotherapy with atebimetinib,

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a poor survival rate, and most patients are not eligible for surgery. Radiation therapy has limited benefit because PDAC tumors are naturally resistant to radiation, using strategies such as low oxygen levels, strong DNA repair systems, and altered cell cycles to survive. To improve radiation effectiveness,

High-voltage electrical pulses (HVEPs) are being used as a non-heat-based treatment for pancreatic cancer. HVEPs work by applying strong electric fields that create tiny pores in cancer cell membranes, a process called electroporation. Lower electric fields temporarily increase cell permeability and make tumors more sensitive to drugs, while stronger fields cause permanent damage that leads

Treatment for metastatic pancreatic cancer is becoming more personalized, moving away from a “one-size-fits-all” approach. Doctors now consider patient age, side-effect tolerance, and tumor genetics, such as KRAS mutations, when selecting therapy. NALIRIFOX, approved in 2024, is now a key first-line option. In the NAPOLI 3 trial, it reduced the risk of death by 16%

Interim results from the LINNOVATE study suggest that a combination of lurbinectedin (Zepzelca), ipilimumab (Yervoy), and nivolumab (Opdivo) is highly effective in advanced soft tissue sarcoma. Early data show nearly all patients achieved disease control, with untreated patients seeing some complete or partial responses. The treatment was generally manageable, though 42% of patients experienced severe

Ginisortamab (UCB6114) is a new monoclonal antibody being developed to treat advanced solid tumors, especially gastrointestinal cancers. Instead of attacking cancer cells directly, it targets the tumor’s surrounding support cells to weaken the tumor’s defenses. The therapy focuses on a protein called gremlin-1, produced by cancer-associated fibroblasts around the tumor. Gremlin-1 blocks natural tumor-suppressing proteins

Researchers have developed an experimental antibody that targets triple-negative breast cancer, one of the most aggressive and treatment-resistant forms of the disease. The antibody focuses on a protein called SFRP2, which helps tumors grow, survive chemotherapy, and evade the immune system. The treatment works by blocking SFRP2, which flips tumor-supporting immune cells called macrophages back into